Crossmark

Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

Crossref DOI link: https://doi.org/10.1007/s12020-018-1751-9

Published Online: 2018-09-24

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bengtsson, D.

Schrøder, H. D.

Berinder, K.

Maiter, D.

Hoybye, C.

Ragnarsson, O.

Feldt-Rasmussen, U.

Krogh Rasmussen, Å.

van der Lely, A.

Petersson, M.

Johannsson, G.

Andersen, M.

Burman, P.
Funding

Funding for this research was provided by:

Skåne University Hospital, Region Skåne, Sweden

Forskningsrådet i Sydöstra Sverige
License Information

Text and Data Mining valid from 2018-09-24
More Information

Article History

Received: 13 July 2018

Accepted: 4 September 2018

First Online: 24 September 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.